Symposia: Multiple Myeloma: Pharmacologic Therapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Drug development, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Drug development, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 10:30 AM-12:00 PM
Pacific Ballroom Salons 21-22
(Marriott Marquis San Diego Marina)
Moderators:
Shohei Mizuno, MD, PhD, Aichi Medical University
and
Nisha S. Joseph, MD, Winship Cancer Institute of Emory University
Disclosures:
Mizuno: Hayashikane Sangyo: Research Funding; Janssen pharmaceutical: Honoraria.
This Session Brings Initial Disclosure of Randomized Trials in Multiple Myeloma and Important Secondary Analysis and Long Term Follow-up of Previously Reported Trials. The Abstracts Presented Will Inform New Evidence for Treatment of Smoldering Multiple Myeloma, New Combinations in the Management of Newly Diagnosed Multiple Myeloma and the Role of Drugs with New Mechanism of Action in the Treatment of Relapsed Multiple Myeloma
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:30 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH